Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Biogen Walloped Wall Street's First Quarter Views; Here's What Happened
06:00am, Wednesday, 29'th Apr 2026
Biogen obliterated Wall Street's first-quarter expectations Wednesday, helped by a nearly perfect sales beat sweep from its growth products.
Will These 5 Drug Bigwigs Surpass Q1 Earnings Forecasts?
01:15pm, Monday, 27'th Apr 2026
LLY, MRK, ABBV, BMY and BIIB are set to report this week as recent beats and key drug demand set up a pivotal Q1 earnings test for pharma giants.
AEGON ASSET MANAGEMENT UK Plc Raises Stock Holdings in Biogen Inc. $BIIB
03:11am, Sunday, 26'th Apr 2026
AEGON ASSET MANAGEMENT UK Plc increased its position in Biogen Inc. (NASDAQ: BIIB) by 33.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (
Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?
10:06am, Friday, 24'th Apr 2026
Biogen heads into Q1 earnings with new drugs like Skyclarys and Zurzuvae driving growth as legacy MS products face rising competitive pressure.
Biogen Inc. $BIIB Shares Bought by Caprock Group LLC
05:16am, Friday, 24'th Apr 2026
Caprock Group LLC raised its holdings in Biogen Inc. (NASDAQ: BIIB) by 318.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The
Biogen Inc. $BIIB Shares Bought by B. Metzler seel. Sohn & Co. AG
04:40am, Friday, 24'th Apr 2026
B. Metzler seel. Sohn and Co. AG raised its position in Biogen Inc. (NASDAQ: BIIB) by 140.1% during the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 29,971 s
Biogen upgraded by UBS on ‘slew of pipeline catalysts' going into 2027
01:17pm, Wednesday, 22'nd Apr 2026
Biogen Inc (NASDAQ:BIIB, XETRA:IDP) has been upgraded to ‘Buy' from ‘Neutral' by UBS analysts, who also raised their price target to $225 from $185, citing growing confidence in a series of clinic
Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline
11:01am, Wednesday, 22'nd Apr 2026
Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
UBS Upgrades Biogen to Buy With a $225 Target: Are the Next 12 Months a Pipeline Catalyst Parade?
10:27am, Wednesday, 22'nd Apr 2026
Biogen (NASDAQ:BIIB | BIIB Price Prediction) picked up a strong endorsement from Wall Street on Wednesday, as UBS analyst Michael Yee upgraded the stock to Buy from Neutral and raised his price target
BIIB Inks Deal to Acquire Rights to Felzartamab in China, Stock Up
12:56pm, Tuesday, 21'st Apr 2026
Biogen gains after securing Greater China rights to felzartamab, giving it worldwide control as phase III studies advance in immune diseases.
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
Wells Fargo Upgrades Biogen to Overweight: Does the Alzheimer's Story Finally Have a Second Act?
11:26am, Monday, 20'th Apr 2026
Biogen (NASDAQ:BIIB) stock just earned a strong endorsement from Wells Fargo on Monday, as analyst Mohit Bansal upgraded the shares to Overweight from Equal Weight and raised his price target to $250
Buy 5 Non-Tech Wide Moat Stocks to Strengthen Your Portfolio
10:07am, Monday, 20'th Apr 2026
BIIB, LMT, NOC, MA and MTD are five non-tech wide moat picks as durable advantages, defense demand, and digital payments growth position these stocks for resilient returns.
Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma
09:02am, Monday, 20'th Apr 2026
Biogen said on Monday it had agreed to pay up to $850 million to acquire exclusive rights in Greater China to an experimental immune disease treatment from Chinese biotech firm TJ Biopharma, giv
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
07:30am, Monday, 20'th Apr 2026
CAMBRIDGE, Mass. and HANGZHOU, China, April 20, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and TJ Biopharma (“TJ Bio”) today announced that the companies have entered into a definitive ag
